Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 24

Cited In for PubMed (Select 21519343)

1.

Molecular genetics of chronic neutrophilic leukemia, chronic myelomonocytic leukemia and atypical chronic myeloid leukemia.

Li B, Gale RP, Xiao Z.

J Hematol Oncol. 2014 Dec 12;7:93. doi: 10.1186/s13045-014-0093-1.

2.

Enforced differentiation of Dnmt3a-null bone marrow leads to failure with c-Kit mutations driving leukemic transformation.

Celik H, Mallaney C, Kothari A, Ostrander EL, Eultgen E, Martens A, Miller CA, Hundal J, Klco JM, Challen GA.

Blood. 2015 Jan 22;125(4):619-28.

PMID:
25416276
3.

Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F.

Lundberg P, Takizawa H, Kubovcakova L, Guo G, Hao-Shen H, Dirnhofer S, Orkin SH, Manz MG, Skoda RC.

J Exp Med. 2014 Oct 20;211(11):2213-30. doi: 10.1084/jem.20131371. Epub 2014 Oct 6.

4.

Mutation analysis of JAK2V617F, FLT3-ITD, NPM1, and DNMT3A in Chinese patients with myeloproliferative neoplasms.

Wang M, He N, Tian T, Liu L, Yu S, Ma D.

Biomed Res Int. 2014;2014:485645. doi: 10.1155/2014/485645. Epub 2014 May 11.

5.

DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies.

Im AP, Sehgal AR, Carroll MP, Smith BD, Tefferi A, Johnson DE, Boyiadzis M.

Leukemia. 2014 Sep;28(9):1774-83. doi: 10.1038/leu.2014.124. Epub 2014 Apr 4. Review. Erratum in: Leukemia. 2015 Feb;29(2):516.

6.

Genetics of myeloproliferative neoplasms.

Viny AD, Levine RL.

Cancer J. 2014 Jan-Feb;20(1):61-5. doi: 10.1097/PPO.0000000000000013. Review.

7.

Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.

Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, Avezov E, Li J, Kollmann K, Kent DG, Aziz A, Godfrey AL, Hinton J, Martincorena I, Van Loo P, Jones AV, Guglielmelli P, Tarpey P, Harding HP, Fitzpatrick JD, Goudie CT, Ortmann CA, Loughran SJ, Raine K, Jones DR, Butler AP, Teague JW, O'Meara S, McLaren S, Bianchi M, Silber Y, Dimitropoulou D, Bloxham D, Mudie L, Maddison M, Robinson B, Keohane C, Maclean C, Hill K, Orchard K, Tauro S, Du MQ, Greaves M, Bowen D, Huntly BJ, Harrison CN, Cross NC, Ron D, Vannucchi AM, Papaemmanuil E, Campbell PJ, Green AR.

N Engl J Med. 2013 Dec 19;369(25):2391-405. doi: 10.1056/NEJMoa1312542. Epub 2013 Dec 10.

8.

A DNMT3A mutation common in AML exhibits dominant-negative effects in murine ES cells.

Kim SJ, Zhao H, Hardikar S, Singh AK, Goodell MA, Chen T.

Blood. 2013 Dec 12;122(25):4086-9. doi: 10.1182/blood-2013-02-483487. Epub 2013 Oct 28.

9.

Epigenetic changes: a common theme in acute myelogenous leukemogenesis.

Gutierrez SE, Romero-Oliva FA.

J Hematol Oncol. 2013 Aug 13;6:57. doi: 10.1186/1756-8722-6-57. Review.

10.

Inherited predisposition to myeloproliferative neoplasms.

Jones AV, Cross NC.

Ther Adv Hematol. 2013 Aug;4(4):237-53. doi: 10.1177/2040620713489144.

11.

Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a.

Quintás-Cardama A, Abdel-Wahab O, Manshouri T, Kilpivaara O, Cortes J, Roupie AL, Zhang SJ, Harris D, Estrov Z, Kantarjian H, Levine RL, Verstovsek S.

Blood. 2013 Aug 8;122(6):893-901. doi: 10.1182/blood-2012-07-442012. Epub 2013 Jun 19.

12.

Perspectives and future directions for epigenetics in hematology.

Goodell MA, Godley LA.

Blood. 2013 Jun 27;121(26):5131-7. doi: 10.1182/blood-2013-04-427724. Epub 2013 May 21. Review.

13.

Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians.

Harrison C, Vannucchi AM.

Ther Adv Hematol. 2012 Dec;3(6):341-54. doi: 10.1177/2040620712459746.

14.

Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts.

Gelsi-Boyer V, Cervera N, Bertucci F, Brecqueville M, Finetti P, Murati A, Arnoulet C, Mozziconacci MJ, Mills KI, Cross NC, Vey N, Birnbaum D.

Haematologica. 2013 Apr;98(4):576-83. doi: 10.3324/haematol.2012.071506. Epub 2012 Oct 12.

15.

Myeloproliferative neoplasm animal models.

Mullally A, Lane SW, Brumme K, Ebert BL.

Hematol Oncol Clin North Am. 2012 Oct;26(5):1065-81. doi: 10.1016/j.hoc.2012.07.007. Epub 2012 Aug 21. Review.

16.

Molecular pathophysiology of myelodysplastic syndromes.

Lindsley RC, Ebert BL.

Annu Rev Pathol. 2013 Jan 24;8:21-47. doi: 10.1146/annurev-pathol-011811-132436. Epub 2012 Aug 28. Review.

17.

Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib.

Mascarenhas J, Mughal TI, Verstovsek S.

Curr Med Chem. 2012;19(26):4399-413. Review.

18.

Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium.

Abdel-Wahab O, Pardanani A, Bernard OA, Finazzi G, Crispino JD, Gisslinger H, Kralovics R, Odenike O, Bhalla K, Gupta V, Barosi G, Gotlib J, Guglielmelli P, Kiladjian JJ, Noel P, Cazzola M, Vannucchi AM, Hoffman R, Barbui T, Thiele J, Van Etten RA, Mughal T, Tefferi A.

Am J Hematol. 2012 May;87(5):562-8. doi: 10.1002/ajh.23169. Epub 2012 Mar 28.

19.

One thousand patients with primary myelofibrosis: the mayo clinic experience.

Tefferi A, Lasho TL, Jimma T, Finke CM, Gangat N, Vaidya R, Begna KH, Al-Kali A, Ketterling RP, Hanson CA, Pardanani A.

Mayo Clin Proc. 2012 Jan;87(1):25-33. doi: 10.1016/j.mayocp.2011.11.001.

20.

Recurrent DNMT3A R882 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.

Lin J, Yao DM, Qian J, Chen Q, Qian W, Li Y, Yang J, Wang CZ, Chai HY, Qian Z, Xiao GF, Xu WR.

PLoS One. 2011;6(10):e26906. doi: 10.1371/journal.pone.0026906. Epub 2011 Oct 31.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk